Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors
NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN's QIAcuity digital PCR platform.
This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples.
'Partnering with QIAGEN enables Tracer to bring our solid tumor MRD expertise to a broader market using a robust digital PCR platform in QIAcuity,' said Mark Kaganovich, CEO of Tracer Biotechnologies. 'With QIAcuity's sensitivity and scalability, we can deliver high-quality companion diagnostics that integrate seamlessly into clinical workflows and offer new options to oncologists and patients.'
Tracer offers two complementary MRD solutions:
Tracer dPCR, a tumor-informed, multiplexed digital PCR assay that allows institutions to run bespoke MRD tests internally using their own digital PCR instruments;
Tracer WGS, an AI-powered whole-genome ctDNA platform that enables ultra-sensitive tumor-agnostic detection and tracking with no need for prior tissue.
'This new partnership represents an important step in further establishing QIAGEN's major role in oncology. We are bringing innovative MRD technologies into drug development through our companion diagnostic partnerships,' said Jonathan Arnold, Vice President, Head of Partnering for Precision Diagnostics at QIAGEN. 'In particular, we want to strengthen our scalable, cost-effective solutions based on our QIAcuity digital PCR system and enable our pharmaceutical partners to use MRD insights for guiding personalized treatment decisions for cancer patients.'
Tracer's mission is to turn every digital PCR machine and next-generation sequencer into a sensitive MRD assay—empowering institutions, pharmaceutical companies, and clinicians with the tools to decentralize testing, accelerate treatment decisions, and personalize cancer care.
About Tracer Biotechnologies
Tracer Biotechnologies is a molecular diagnostics company specializing in blood-based assays for cancer detection and monitoring. Our platform enables decentralized, high-performance MRD testing using either digital PCR or whole-genome sequencing—bringing precision oncology closer to the point of care. For more information visit www.tracerbio.com.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
'Water parasite could cost me sight in one eye'
A woman fears she could partially lose her sight after a water parasite "burrowed" into her eye when she went swimming while wearing contact lenses. Nicola Greenfield, of Rendlesham, Suffolk, has been diagnosed with acanthamoeba keratitis, a painful infection of the cornea - the outer layer that protects the eye. The 58-year-old sought help after her vision became blurred and her right eye started to feel "really sore" and sensitive to light while she was working on her computer. "My vision is incredibly blurred and it feels a bit like getting chilli, lemon juice or bleach in your eye," said Mrs Greenfield, who has had to be signed off work. "The worst case scenario is I lose sight in my right eye and the best case scenario is I lose a little bit – but I am just going to do what I can to try and get better," said Mrs Greenfield. "Since I started treatment it has got a little better, but I am having to wear dark glasses and put blankets against my curtains because I can't bear the light." According to the NHS's Moorfields Eye Hospital website, around two in 100,000 contact lens wearers per year in the UK are diagnosed with acanthamoeba keratitis. The infection is caused by a microscopic organism usually found in bodies of water as well as domestic tap water, swimming pools, hot tubs, soil and air. Some patients can recover within three to six months, while more complicated cases can prove debilitating for as long as a year. Mrs Greenfield was advised to go to Ipswich Hospital after her optician declared she was suffering from a "medical emergency" and needed urgent attention. She has since undergone numerous examinations, biopsies and intensive treatment and has had surgery to remove the top layer of her cornea. "If you wear contact lenses [the parasite] can get trapped behind the lens and start to burrow into the eye," she said. "It is incredibly rare but that, unfortunately, is what's happened to me." Vision Direct says swimming with "contact lenses or getting them wet should be avoided at all times" as doing so can make eyes "vulnerable to contamination by harmful bacteria". Mrs Greenfield, who has worn contact lenses for 40 years, has now warned others to wear goggles and be mindful of purchasing lenses on the internet. "I was always told not to sleep in contact lenses, that was a big no-no, but I don't know why opticians are not telling people not to wear them when they shower or swim," she told the BBC. "Behind the lens is a lovely, warm environment for a germ to breed so people need to be really, really careful. "If I had known then I wouldn't have worn my lenses while swimming." Max Halford, clinical and policy director of the Association of British Dispensing Opticians, said opticians "will always advise on how to handle, clean and replace your contact lenses". "Every UK-based contact lens optician should always provide advice on the correct care and usage of contact lenses both at the initial fitting appointment and at every follow up," he said. "We recommend patients always attend their local opticians for routine contact lenses appointments, usually every 24 months or more often if recommended by your eye care professional. "These appointments are a vital part of your eye health regime if you are a contact lens wearer and they are an opportunity for your optician to review and check the correct procedures are being followed for successful contact lens wear. "Always check with the supplier of your contact lenses that after appointments and advice is available including advice on what to do in an emergency." Follow Suffolk news on BBC Sounds, Facebook, Instagram and X. Woman's eyesight saved by cutting-edge test after mystery infection 'My patients complain about dazzling headlights' 'I never expected I would get to 29 and not see' Moorfields Eye Hospital
Yahoo
26 minutes ago
- Yahoo
Markel International appoints Sucheng Chang to lead Asia Pacific operations
LONDON, June 9, 2025 /PRNewswire/ -- Markel Insurance, the insurance operations within Markel Group Inc. (NYSE:MKL), today announced that it has appointed Sucheng Chang as its new Managing Director for Asia Pacific, with effect from 14 July. In his new role, Chang will head up Markel International's Asia Pacific business, which operates from its regional hub in Singapore and from offices in Australia, Hong Kong, China, India, Malaysia and Dubai. He will be responsible for leading the strategic direction of the business, centered on maximizing profitable growth and delivering exceptional client and broker service. Markel International's Asia Pacific business has witnessed significant expansion in recent years, following investment made as part of its Accelerate Asia Pacific strategy. Since 2019, GWP has increased by approximately 600%, underwriting profitability has improved and the number of employees in the region has increased by nearly 300%. Chang will take over from Christian Stobbs, who earlier this year announced his decision to leave the Asia Pacific region, remaining with Markel in another role. Commenting on Chang's appointment, Andrew McMellin, President of Markel International, said: "Sucheng is a highly strategic and well-respected leader within the Asia Pacific market, and I'm thrilled that he's joining Markel to lead our regional business in the next phase of its development. The Accelerate Asia Pacific strategy is a cornerstone of the profitable growth agenda at Markel International. I've no doubt that Sucheng's leadership qualities and his significant experience of scaling insurance operations in Asia will help us to build on this momentum as we push it forward to even greater success." Chang added: "Markel has made huge inroads in Asia Pacific and today is a well-respected insurance partner to clients and trading partners in the region, renowned for its focus on exceptional service and customer outcomes. I therefore couldn't be more excited to lead the next phase of the expansion of Markel's Asia Pacific business, building on the progress that's been made to expand our presence even further and take advantage of the opportunities available in the US$300-billion GWP Asia-Pacific insurance market." Chang arrives at Markel with significant experience scaling insurance operations across the Asia Pacific, most recently as Chief Executive Officer, Hong Kong, for Aon. Prior to joining Aon, Chang spent more than 13 years at Liberty Mutual in strategic roles, including Chief Distribution Officer, Global Retail Markets East and Chief Executive Officer of Liberty Insurance Singapore. He holds an MBA from Yale University and BA from Boston University. About Markel Insurance We are Markel Insurance, a leading global specialty insurer with a truly people-first approach. As the insurance operations within the Markel Group Inc. (NYSE: MKL), we leverage a broad array of capabilities and expertise to create intelligent solutions for the most complex specialty insurance needs. However, it is our people – and the deep, valued relationships they develop with colleagues, brokers and clients – that differentiates us worldwide. View original content to download multimedia: SOURCE Markel
Yahoo
an hour ago
- Yahoo
High Growth Tech Stocks To Watch In Europe June 2025
As the European markets experience a boost, with the STOXX Europe 600 Index climbing by 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are increasingly focusing on high-growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that can leverage favorable economic conditions and technological advancements to drive substantial growth. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 226 stocks from our European High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across several countries including the United States, Japan, China, and the Netherlands, with a market cap of €31.52 billion. Operations: argenx focuses on developing therapies for autoimmune diseases, generating revenue primarily from its biotechnology segment, which reported $2.64 billion. The company's operations span multiple countries, including the United States, Japan, China, and the Netherlands. argenx SE has demonstrated remarkable growth with a surge in revenue to $807.37 million, doubling from the previous year's $412.51 million, alongside transitioning from a net loss to a substantial net income of $169.47 million. This financial turnaround is underscored by robust R&D commitments, crucial for sustaining innovation and competitiveness in the biotech landscape. The firm's recent CHMP nod for VYVGART® in CIDP treatment further highlights its strategic focus on expanding therapeutic applications, promising continued relevance and impact within the healthcare sector. Click here to discover the nuances of argenx with our detailed analytical health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of approximately €1.72 billion. Operations: The company's revenue primarily comes from Premium Solutions, generating €924.24 million, while Automated Solutions contribute €64.59 million. Believe, a European tech entity, is navigating its path towards profitability with expected earnings growth of 96.9% annually. Despite current unprofitability, its revenue growth outpaces the French market's average at 13.4% per year compared to 5%. This growth trajectory is supported by strategic moves such as the proposed acquisition by TCMI Inc., EQT X, and Denis Ladegaillerie for a €57.9 million stake, enhancing financial stability and market presence. Moreover, Believe's commitment to R&D aligns with industry demands for continuous innovation, ensuring it remains competitive in the dynamic tech landscape. Get an in-depth perspective on Believe's performance by reading our health report here. Examine Believe's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Comet Holding AG, along with its subsidiaries, delivers X-ray and radio frequency (RF) power technology solutions globally across Europe, North America, and Asia, with a market capitalization of CHF1.79 billion. Operations: The company generates revenue through three main segments: X-Ray Systems (CHF115.89 million), Industrial X-Ray Modules (CHF94.57 million), and Plasma Control Technologies (CHF247.39 million). Comet Holding AG, a Swiss tech firm, is making notable strides with an earnings growth of 37.3% annually, significantly outpacing the local market's average of 10.7%. This robust performance is further underscored by its revenue increase of 12.2% per year, which also surpasses the Swiss market growth rate of 4.2%. Notably, Comet's commitment to innovation is evident in its R&D spending, crucial for maintaining technological leadership in a competitive sector. Recent corporate actions include electing Benjamin Loh as Chairman and approving a dividend increase to CHF 1.50 per share, signaling strong governance and shareholder confidence amidst a promising financial trajectory marked by first-quarter sales surging by 37.5% year-over-year to CHF 111.2 million. Take a closer look at Comet Holding's potential here in our health report. Assess Comet Holding's past performance with our detailed historical performance reports. Dive into all 226 of the European High Growth Tech and AI Stocks we have identified here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX ENXTPA:BLV and SWX:COTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
